Klinische NET-Studien

CLARINET FORTE

Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with lanreotide Autogel® 120 mg administered every 28 days”as amended from time to time and incorporated herein by reference

Ansprechpartner: Dr. H. Jann, Dr. U.-F. Pape

COMPETE

A prospective, randomised, Controled, Open-label, Multicentre phase lll study  to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSIR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET)

Ansprechpartner: Dr. H. Jann, Dr. U.-F. Pape

EVINEC 

Safety and tolerability of Everolimus as second-line treatment in poorly differenciated neuroendocrine carcinoma/neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumor G3- an investigational initialled Phase II study/EVINEC

Ansprechpartner: Dr. H. Jann, Dr. U.-F. Pape

NETTER-I

Eine multizentrische, stratifizierte, offene, randomisierte, vergleichsarmkontrollierte Parallelgruppenstudie der Phase-III zum Vergleich der Behandlung mit 177Lu-DOTA0-Tyr3-Octreotat mit langwirksamem Octreotid bei Patienten mit inoperablen, progressiven, somatostatinrezeptorpositiven Karzinoidtumoren des Mitteldarms.

Ansprechpartner: Dr. H. Jann, Dr. U.-F. Pape

REMINET

An European multicenter phase II/III, randomized double-blind placebo controlled study evaluating lanreotide as maintenance therapy in patients with non–resectable duodeno-pancreatic neuroendocrine tumours after first line treatment with systemic chemotherapy

Ansprechpartner: Dr. H. Jann, Dr. U.-F. Pape

SEQTOR

Randomized open label study to compare the efficacy and safety of Everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by Everolimus upon progression, in advanced progressive pNETs

Ansprechpartner: Dr. H. Jann, Dr. U.-F. Pape